In CRC cells, it has been demonstrated that the increase of DR-5 enhances cytotoxic effects of 5-fluorouracil and oxaliplatin.14 Here, we hypothesized that the GALNT14 genotype might also affect the outcome of stage III CRC patients and examined the clinicopathological parameters in relationship to GALNT14 genotype and the prognosis predictive values of these factors. The gene discussed is GALNT14; the disease is colorectal carcinoma.